Effectiveness of Systemic Immune-Inflammatory Index in Predicting Bone Metastasis in Newly Diagnosed Prostate Cancer Patients

Objective To explore the effectiveness of systemic immune inflammation index (Systemic immune-inflammation index, SII) in predicting bone metastasis in patients with newly diagnosed prostate cancer (Prostatic cancer, PCa). Methods The retrospective analysis of 200 cases of prostate cancer from January 2020 to June 2023 and 70 cases of bone metastasis compared the expression difference of SII between the two groups and analyzed the clinical diagnostic value of SII in prostate cancer bone metastasis. The resulting SII in the bone metastasis group was 500.63(351.24-696.57) 109/ L, the SII in the no-bone metastasis group was 350.12(258.41-529.40) 109/ L, statistically significant, P <0.05. The ROC curve analysis revealed that its sensitivity was 68.63% and its specificity was 60.95%. Conclusion System immune inflammation index (SII) has certain application value for bone metastasis in patients with newly diagnosed prostate cancer (PCa), and high level of SII indicates poor prognosis, which is worth further clinical study.